INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer

BACKGROUND: Triple negative breast cancer (TNBC) accounts for 10-20% of breast cancers but has no specific therapy. While TNBC may be more sensitive to chemotherapy than other types of breast cancer, it has a poor prognosis. Most TNBC relapses occur during the five years following treatment, however...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Front Oncol
Hoofdauteurs: Veyssière, Hugo, Lusho, Sejdi, Molnar, Ioana, Kossai, Myriam, Bernadach, Maureen, Abrial, Catherine, Bidet, Yannick, Radosevic-Robin, Nina, Durando, Xavier
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2021
Onderwerpen:
Oncology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8268015/
https://ncbi.nlm.nih.gov/pubmed/34249690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.653370
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items